BVI has received CE marking for its Virtuoso® platform, the first dual-function phaco-vitrectomy system designed to enhance control, efficiency, and versatility in both cataract and vitreoretinal surgeries. The first patient was successfully treated in December 2025 at LMU Klinikum in Munich, marking a significant milestone for the platform. This achievement builds on Virtuoso®’s presence at major industry forums in 2025, including EURETINA and ESCRS, and its live demonstration at the Munich Retina Meeting in 2026, showcasing its innovative design focused on fluidic stability and workflow efficiency.

The clinical significance of Virtuoso® lies in its advanced features, such as the Equality™ fluidic control system, which maintains intraocular pressure throughout procedures, and the Resolute™ ultrasound delivery system, which optimizes energy delivery regardless of lens hardness. These innovations are pivotal for improving surgical outcomes, as evidenced by clinical data presented at recent conferences, indicating enhanced energy consistency and suction performance compared to leading platforms. The platform is positioned to meet the evolving demands of multidisciplinary centers and outpatient surgical environments, reflecting BVI’s commitment to providing flexible, future-proof solutions for surgeons.

The takeaway from this development is the potential shift in surgical paradigms for combined anterior and posterior segment procedures. Virtuoso® not only streamlines surgical workflows but also enhances the precision and efficiency of operations, which could accelerate the adoption of dual-function platforms in clinical settings. As BVI prepares for commercial availability in Q3 2026, this platform may significantly impact the landscape of ophthalmic surgical devices, aligning with the industry’s push for integrated, high-performance solutions that cater to complex surgical needs.

Source: globenewswire.com